• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国冠心病门诊患者的基线特征和他汀类药物干预的性别差异:中国胆固醇教育计划。

The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China Cholesterol Education Program.

机构信息

Heart, Lung, and Blood Vessel Center of Tongji University, Shanghai, China.

出版信息

Clin Cardiol. 2009 Jun;32(6):308-14. doi: 10.1002/clc.20514.

DOI:10.1002/clc.20514
PMID:19569062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6653262/
Abstract

BACKGROUND

The China Cholesterol Education Program (CCEP) aimed to investigate the baseline characteristics of outpatients with coronary heart disease (CHD) according to gender, especially lipid levels, statin intervention, and rates of achieving their goal low-density lipoprotein cholesterol (LDL-C) level.

METHODS

A total of 4778 CHD outpatients were enrolled from 52 centers in 6 Chinese cities from January 2006 to January 2007.

RESULTS

Female outpatients were significantly older than male outpatients (66+/-10 vs 63+/-11 years, P <0.001). Male outpatients were more likely to smoke than female outpatients (P<0.001). Female outpatients had a higher prevalence of hypertension, diabetes mellitus, LDL-C level, and total cholesterol level (all P values <0.001). About 82% of the participants received statin therapy. The LDL-C levels were 3.06+/-1.08 mmol/L and 2.89+/-0.97 mmol/L in outpatients at high risk and very high risk respectively (P<0.001). Though there were higher rates of statin intervention, only 36.2% of the high risk outpatients got to the target LDL-C level (<2.6 mmol/L); 10.9% of the very high risk outpatients achieved the optimal LDL-C level (<1.82 mmol/L) suggested by National Cholesterol Education Program Adult Treatment Panel III. The rate of achieving target was only 42.2%, even when LDL-C <2.6 mmol/L was the target level for patients at very high risk. Only 19.4% of the outpatients at very high risk achieved the target (LDL-C <2.08 mmol/L) suggested by the updated Chinese guideline for CHD.

CONCLUSION

Although the outpatients received a higher rate of statin therapy, the rates of achieving the target were lower. There is still a significant gap between the guidelines and clinical practice in statin intervention among these CHD outpatients, particularly for women.

摘要

背景

中国胆固醇教育计划(CCEP)旨在根据性别调查冠心病(CHD)门诊患者的基线特征,特别是血脂水平、他汀类药物干预以及实现低密度脂蛋白胆固醇(LDL-C)目标水平的比例。

方法

2006 年 1 月至 2007 年 1 月,从中国 6 个城市的 52 个中心共招募了 4778 例 CHD 门诊患者。

结果

女性门诊患者明显比男性门诊患者年长(66+/-10 岁比 63+/-11 岁,P<0.001)。男性门诊患者比女性门诊患者更可能吸烟(P<0.001)。女性门诊患者高血压、糖尿病、LDL-C 水平和总胆固醇水平的患病率更高(均 P<0.001)。约 82%的患者接受了他汀类药物治疗。高危和极高危患者的 LDL-C 水平分别为 3.06+/-1.08 mmol/L 和 2.89+/-0.97 mmol/L(P<0.001)。尽管他汀类药物干预率较高,但仅有 36.2%的高危患者达到 LDL-C 目标值(<2.6 mmol/L);10.9%的极高危患者达到了美国国家胆固醇教育计划成人治疗专家组 III 建议的最佳 LDL-C 水平(<1.82 mmol/L)。即使 LDL-C<2.6 mmol/L 是极高危患者的目标水平,达到目标的比例也只有 42.2%。极高危患者中只有 19.4%达到了更新的中国冠心病指南建议的目标值(LDL-C<2.08 mmol/L)。

结论

尽管门诊患者接受了更高的他汀类药物治疗率,但达到目标的比例较低。这些冠心病门诊患者的他汀类药物干预在指南和临床实践之间仍存在显著差距,尤其是女性患者。

相似文献

1
The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China Cholesterol Education Program.中国冠心病门诊患者的基线特征和他汀类药物干预的性别差异:中国胆固醇教育计划。
Clin Cardiol. 2009 Jun;32(6):308-14. doi: 10.1002/clc.20514.
2
Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: the China Cholesterol Education Program (CCEP).
Circ J. 2008 Dec;72(12):2040-5. doi: 10.1253/circj.cj-08-0417. Epub 2008 Oct 21.
3
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.来自24个欧洲国家的冠心病患者的降脂药物治疗——EUROASPIRE IV调查结果
Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.
4
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.来自 3 个数据源的他汀类药物治疗患者的血脂异常患病率和血脂达标情况:一项回顾性分析。
J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.
5
Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study.2 型糖尿病合并冠心病患者中血脂达标率的性别差异:来自 CCMR-3B 研究的结果。
Sci Rep. 2017 Oct 4;7(1):12648. doi: 10.1038/s41598-017-13066-z.
6
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.在老年患者中,依折麦布联合他汀类药物持续治疗对改善血脂谱及实现低密度脂蛋白胆固醇目标的有效性:一项随机、双盲、安慰剂对照试验数据的亚组分析
Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28.
7
Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.降脂治疗与中国福州高危心血管风险患者的低密度脂蛋白胆固醇(LDL-C)目标达标情况。
J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):307-315. doi: 10.1177/1074248419899298. Epub 2020 Jan 10.
8
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.医学降脂治疗:当前证据、正在进行的试验及未来发展
Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003.
9
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.依折麦布/辛伐他汀与辛伐他汀在伴有或不伴有糖尿病的冠心病患者中的应用比较。
Lipids Health Dis. 2010 Jul 27;9:80. doi: 10.1186/1476-511X-9-80.
10
The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study.经皮冠状动脉介入治疗后冠心病患者血脂水平分析:一项为期一年的随访观察研究。
Lipids Health Dis. 2020 Jul 6;19(1):163. doi: 10.1186/s12944-020-01340-5.

引用本文的文献

1
Glycemic control and risk factors for in-hospital mortality and vascular complications after coronary artery bypass grafting in patients with and without preexisting diabetes.在有和没有糖尿病的患者中,冠状动脉旁路移植术后血糖控制与住院死亡率和血管并发症的危险因素。
J Diabetes. 2021 Mar;13(3):232-242. doi: 10.1111/1753-0407.13108. Epub 2020 Sep 14.
2
The Study of Clustering Effects of Behavior Risk Factors in Patients with Metabolic Syndrome in Southern China: A Cross-Sectional Study.中国南方代谢综合征患者行为危险因素聚类效应的研究:一项横断面研究。
J Diabetes Res. 2020 Jul 1;2020:6478393. doi: 10.1155/2020/6478393. eCollection 2020.
3
Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012-2018).上海金山区医院信息系统中他汀类药物处方的流行率、起始治疗、剂量强度和利用的时间趋势分析(2012-2018 年)。
BMC Cardiovasc Disord. 2020 Apr 25;20(1):201. doi: 10.1186/s12872-020-01482-5.
4
Cardioprotective medication adherence among patients with coronary heart disease in China: a systematic review.中国冠心病患者的心脏保护药物依从性:一项系统评价
Heart Asia. 2019 Jun 24;11(2):e011173. doi: 10.1136/heartasia-2018-011173. eCollection 2019.
5
Characteristics of lipid profiles and lipid control in patients with diabetes in a tertiary hospital in Southwest China: an observational study based on electronic medical records.中国西南某三级医院糖尿病患者血脂特征及血脂控制情况:基于电子病历的观察性研究。
Lipids Health Dis. 2019 Jan 12;18(1):13. doi: 10.1186/s12944-018-0945-8.
6
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.阿拉伯海湾地区糖尿病患者血脂异常管理和结局的性别差异:CEPHEUS 研究的结果。
Lipids Health Dis. 2018 Feb 5;17(1):25. doi: 10.1186/s12944-018-0667-y.

本文引用的文献

1
Perspectives on dyslipidemia and coronary heart disease in women: an update.女性血脂异常与冠心病的研究进展:最新综述
Curr Opin Cardiol. 2006 Nov;21(6):602-7. doi: 10.1097/01.hco.0000245739.47712.0a.
2
Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.冠心病血脂异常管理中性别差异的回顾性研究:对来自马里兰州一家健康维护组织的患者数据的分析
Clin Ther. 2006 Apr;28(4):591-9. doi: 10.1016/j.clinthera.2006.04.012.
3
[Serum total cholesterol and 10-year cardiovascular risk in a Chinese cohort aged 35-64 years].[中国35-64岁队列人群的血清总胆固醇与10年心血管疾病风险]
Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Feb;34(2):169-73.
4
Epidemiology of coronary heart disease in women.女性冠心病的流行病学
Heart. 2006 May;92 Suppl 3(Suppl 3):iii2-4. doi: 10.1136/hrt.2005.070227.
5
The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.
J Atheroscler Thromb. 2005;12(6):338-42. doi: 10.5551/jat.12.338.
6
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.阿托伐他汀强化降脂治疗稳定型冠心病患者
N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8.
7
Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.香港华裔冠心病高危患者他汀类药物治疗依从性与血脂控制的关联。
Br J Clin Pharmacol. 2004 Nov;58(5):528-35. doi: 10.1111/j.1365-2125.2004.02202.x.
8
Cardiovascular disease risk factor levels and their relations to CVD rates in China--results of Sino-MONICA project.中国心血管疾病危险因素水平及其与心血管疾病发病率的关系——中国MONICA项目结果
Eur J Cardiovasc Prev Rehabil. 2004 Aug;11(4):275-83. doi: 10.1097/01.hjr.0000136566.89429.63.
9
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗组第三次指南的影响。
Circulation. 2004 Jul 13;110(2):227-39. doi: 10.1161/01.CIR.0000133317.49796.0E.
10
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study.与中国多省队列研究相比,弗雷明汉冠心病风险评估工具对中国人群的预测价值。
JAMA. 2004 Jun 2;291(21):2591-9. doi: 10.1001/jama.291.21.2591.